Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

Farastuk Bozorgmehr1,2*, Inn Chung1,2, Petros Christopoulos1,2, Johannes Krisam3, Marc A. Schneider2,4, Lena Brückner1,2, Daniel Wilhelm Mueller5, Michael Thomas1,2 and Stefan Rieken6

Following publication of the original article [1], the authors want to clarify the wording of two sentences.

In the line of the study procedures section “In total, 44 patients will be enrolled per group. After n=18 patients have been enrolled to the HYPO- or CON-treatment arm, respectively, an interim efficacy analysis for the respective arm will be conducted based on the objective response rate (ORR) at 12 weeks after first durvalumab administration”, the sentence was refined to “[…] the objective response rate (ORR), when the 18th patient in each arm has undergone first radiographic assessment (at 12 weeks after first durvalumab administration).”

In the study endpoint section, in the line “The ORR evaluated 12 weeks after first durvalumab administration (according to RECIST 1.1) is set as the primary efficacy endpoint.”, the sentence changed to “The ORR according to RECIST 1.1 is set as the primary efficacy endpoint.”

Published online: 10 August 2023

References

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.